Drug insight: Thalidomide as a treatment for multiple myeloma

Nature Clinical Practice Oncology

Volumn 2, Issue 5, 2005, Pages 262-270

  Kumar, Shaji ^a   Anderson, Kenneth C ^b,c  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Immunomodulatory drug; Multiple myeloma; Stroma; Thalidomide; Tumor microenvironment

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

BIRTH DEFECT; BONE MARROW CANCER; BONE MARROW CELL; BRADYCARDIA; CANCER GROWTH; CELL INTERACTION; CELL SURVIVAL; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DROWSINESS; DRUG ACTIVITY; DRUG DESIGN; DRUG ERUPTION; DRUG STRUCTURE; ENDOTHELIUM CELL; FATIGUE; HEADACHE; HEPATITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOTHYROIDISM; IMMUNOMODULATION; IMPOTENCE; IN VITRO STUDY; IN VIVO STUDY; LEG CRAMP; MALAISE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; OSTEOBLAST; OSTEOCLAST; OUTCOMES RESEARCH; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLASMA CELL; PRIORITY JOURNAL; PRURITUS; REVIEW; SOMNOLENCE; STEVENS JOHNSON SYNDROME; STROMA CELL; THROMBOCYTOPENIA; TREMOR; TUMOR MODEL; XEROSTOMIA;

ANIMALS; BONE MARROW CELLS; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, SCID; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 20444491613     PISSN: 17434254     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncponc0174     Document Type: Review

References (58)

1. Jemal A et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10-30
2. Attal M and Harousseau JL (1999) Autologous peripheral blood progenitor cell transplantation for multiple myeloma. Baillieres Best Pract Res Clin Haematol 12: 171-191
3. Anderson KC (2003) Moving disease biology from the lab to the clinic. Cancer 97: 796-801
4. Hideshima T et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950
5. Richardson PG et al. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100: 3063-3067
6. Hideshima T et al. (2004) Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618
7. Hideshima T et al. (2002) The biological sequelae of stromal cell-derived factor-1 alpha in multiple myeloma. Mol Cancer Ther 1: 539-544
8. Asosingh K (2003) Migration, adhesion and differentiation of malignant plasma cells in the 5T murine model of myeloma. Verh K Acad Geneeskd Belg 65: 127-134
9. Uchiyama H et al. (1992) Characterization of adhesion molecules on human myeloma cell lines. Blood 80: 2306-2314
10. Abe M et al. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104: 2484-2491
11. Kumar S et al. (2004) Endothelial cells induce multiple myeloma cell proliferation protect against conventional and novel therapies [abstract]. Blood 104: a2354
12. Chauhan D et al. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104-1112
13. Tai YT et al. (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3′-kinase/AKT signaling. Cancer Res 63: 5850-5858
14. Podar K and Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105: 1383-1395
15. Gupta D et al. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961
16. Podar K et al. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98: 428-435
17. Rajkumar SV et al. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 8: 2210-2216
18. Kumar S et al. (2004) Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. Leukemia 18: 624-627
19. Kumar S et al. (2004) Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. Blood 104: 1159-1165
20. Damiano JS et al. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93: 1658-1667
21. Roodman GD (2004) Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 32: 290-292
22. Urashima M et al. (1997) The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 90: 754-765
23. Mitsiades CS et al. (2003) Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 63: 6689-6696
24. Singhal S et al. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571
25. Eriksson T et al. (2001) Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 57: 365-376
26. Aweeka F et al. (2001) Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. J Clin Pharmacol 41: 1091-1097
27. Mitsiades N et al. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 99: 4525-4530
28. Chauhan D et al. (1997) Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 15: 837-843
29. Lentzsch S et al. (2003) Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 17: 41-44
30. Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25: 53-57
31. LeBlanc R et al. (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103: 1787-1790
32. McHugh SM et al. (1995) The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Thl cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99: 160-167
33. Davies FE et al. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216
34. Barlogie B et al. (2000) Long term follow up of 169 patients receiving a phase 11 trial of single agent thalidomide for advanced and refractory multiple myeloma (MM) [abstract]. Blood 96: a2213
35. Grosbois B et al. (2001) Thalidomide (Thal) in the Treatment of advanced multiple myeloma (MM). A prospective study of 120 patients [abstract]. Blood 98: a689
36. Kumar S et al. (2003) Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78: 34-39
37. Schey SA et al. (2004) Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22: 3269-3276
38. Tricot G et al. (2001) Angiochemotherapy (ACT) for multiple myeloma (MM) with DT-PACE results in a high response rate, but in contrast to tandem transplants with melphalan does not affect durable disease control [abstract]. Blood 98: a3531
39. Weber D et al. (2003) Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16-19
40. Rajkumar SV et al. (2002) Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20: 4319-4323
41. Rajkumar SV et al. (2004) Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (ElAOO): results of a phase III trial coordinated by the Eastern Cooperative Oncology Group [abstract]. Blood 104: a205
42. Stewart KA et al. (2004) Results of a multi-center randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma following autologous stem cell transplant [abstract]. Blood 104: a335
43. Attal M et al. (2004) Maintenance treatment with thalidomide after autologous transplantation for myeloma: first analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02) [abstract]. Blood 104: a535
44. Alexanian R et al. (2003) Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma. Ann Oncol 13: 1116-1119
45. Fahdi IE et al. (2004) Bradycardia during therapy for multiple myeloma with thalidomide. Am J Cardiol 93: 1052-1055
46. Tosi P et al. (2002) Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 87: 408-414
47. Schey SA et al. (2003) An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leuk Res 27: 909-914
48. Hus M et al. (2001) Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 86: 404-408
49. Durie BG (2002) Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol 29: 34-38
50. Rajkumar SV et al. (2003) Thalidomide as initial therapy for early-stage myeloma. Leukemia 17: 775-779
51. Juliusson G et al. (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 109: 89-96
52. Garcia-Sanz R et al. (2004) The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 18: 856-863
53. Kropff MH et al. (2003) Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 122: 607-616
54. Offidani M et al. (2004) Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma. Hematol J 5: 312-317
55. Dimopoulos MA et al. (2004) Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma ≥ 75 years of age [abstract]. Blood 104: a1482
56. Palumbo A et al. (2004) A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis [abstract]. Blood 104: a207
57. Zangari M et al. (2004) Marked activity of velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM) [abstract]. Blood 104: a1480
58. Alexanian R et al. (2004) VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract]. Blood 104: a210